Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cordis Corp. Receives FDA Clearance For ADROIT Guiding Catheter - Quick Facts

RELATED NEWS
Trade JNJ now with 

Cordis Corporation, part of the Johnson & Johnson Family of Companies (JNJ: Quote) announced that it has received clearance from the Food and Drug Administration or FDA of its latest innovation in guiding catheters: the ADROIT 6F Guiding Catheter.

The ADROIT Catheter's innovative hybrid braid wire technology not only enables the production of a guide catheter with the largest lumen size on the U.S. market, it also facilitates better control and back up support. In addition, the new innovative design incorporating a flexible distal segment and soft longer tip allows atraumatic placement and stability, the company stated.

Cordis said that the ADROIT Guiding Catheter provides a wide range of shapes, including extra back-up shapes and radial specific shapes to support treatment needs of various coronary anatomies.

Click here to receive FREE breaking news email alerts for Johnson & Johnson and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.